Abstract:Inhibitors of the p53-MDM2 interaction such as RG7388 have been developed to exploit latent tumor suppressive properties in p53 in 50% of tumors in which p53 is wild-type. However, these agents for the most part activate cell cycle arrest rather than death, and high doses in patients elicit on-target dose-limiting neutropenia. Recent work from our group indicates that combination of p53-MDM2 inhibitors with the class-I HDAC inhibitor Entinostat (which itself has dose-limiting toxicity issues) has the potential to significantly augment cell death in p53 wild-type colorectal cancer cells. We investigated whether coencapsulation of RG7388 and Entinostat within polymeric nanoparticles (NPs) could overcome efficacy and toxicity limitations of this drug combination. Combinations of RG7388 and Entinostat across a range of different molar ratios resulted in synergistic increases in cell death when delivered in both free drug and nanoencapsulated formats in all colorectal cell lines tested. Importantly, we also explored the <i>in vivo</i> impact of the drug combination on murine blood leukocytes, showing that the leukopenia induced by the free drugs could be significantly mitigated by nanoencapsulation. Taken together, this study demonstrates that formulating these agents within a single nanoparticle delivery platform may provide clinical utility beyond use as nonencapsulated agents.

What problem does this paper attempt to address?

The problems that this paper attempts to solve mainly focus on two aspects: 1. **Improving drug efficacy**: Through nano - encapsulation technology, the MDM2 inhibitor RG7388 and the class I histone deacetylase (HDAC) inhibitor Entinostat are co - encapsulated in polymer nanoparticles to enhance their synergistic anti - tumor effect on colorectal cancer cells. Specifically, the researchers hope that this combination can overcome the limitations of single drugs in inducing apoptosis and improve the treatment effect. 2. **Reducing systemic toxicity**: The researchers hope to reduce the dose - limiting toxicity of these two drugs in clinical applications through nano - encapsulation technology, especially hematological toxicity (such as leukopenia, thrombocytopenia, etc.). These toxicities are one of the main obstacles limiting the wide application of these two drugs in cancer treatment. ### Research background - **p53 - MDM2 interaction**: p53 is an important tumor suppressor factor, and its activity is negatively regulated by MDM2. MDM2 inhibitors (such as RG7388) activate p53 by disrupting the p53 - MDM2 interaction, thereby exerting an anti - tumor effect. However, these inhibitors usually only cause cell cycle arrest rather than cell death, and high - dose use will lead to dose - limiting toxicity, such as neutropenia. - **HDAC inhibitors**: Entinostat is a class I HDAC inhibitor, which can reduce the expression of FLIP (an anti - apoptotic protein), thereby enhancing the apoptotic effect of MDM2 inhibitors. However, Entinostat itself also has dose - limiting toxicity. ### Research methods - **Nanoparticle preparation**: The researchers prepared polymer nanoparticles (NPs) loaded with RG7388 and Entinostat by the nanoprecipitation method, and achieved the best synergistic effect by optimizing the drug ratio (1:2). - **Cell experiments**: The pharmacological effects of nanoparticles in multiple colorectal cancer cell lines were evaluated by methods such as cell viability assay, cell cycle analysis, and apoptosis detection. - **In vivo experiments**: The hematological toxicity of nanoparticles in vivo was evaluated through mouse models, and the toxicity differences between free drugs and nano - encapsulated drugs were compared. ### Main findings - **Synergistic anti - tumor effect**: Nanoparticles loaded with RG7388 and Entinostat showed a significant synergistic anti - tumor effect in multiple colorectal cancer cell lines, especially the ability to induce apoptosis was significantly enhanced. - **Reduced toxicity**: Nano - encapsulated drugs significantly reduced hematological toxicity in mouse models, especially in terms of white blood cell count. Compared with free drugs, the toxicity of nano - encapsulated drugs was significantly reduced. ### Conclusion This study shows that co - encapsulating RG7388 and Entinostat in polymer nanoparticles through nano - encapsulation technology can not only significantly enhance their synergistic anti - tumor effect, but also effectively reduce dose - limiting toxicity. This finding provides new ideas for the development of safer and more effective cancer treatment methods.

Nanoencapsulation of MDM2 Inhibitor RG7388 and Class-I HDAC Inhibitor Entinostat Enhances their Therapeutic Potential Through Synergistic Antitumor Effects and Reduction of Systemic Toxicity

Combinational delivery of hydrophobic and hydrophilic anticancer drugs in single nanoemulsions to treat MDR in cancer

Amplified antitumor efficacy by a targeted drug retention and chemosensitization strategy-based “combo” nanoagent together with PD-L1 blockade in reversing multidrug resistance

Discovery of Novel p53-MDM2 Inhibitor (RG7388)-Conjugated Platinum IV Complexes as Potent Antitumor Agents

Synergistic Inhibition of Drug-Resistant Colon Cancer Growth with PI3K/mTOR Dual Inhibitor BEZ235 and Nano-Emulsioned Paclitaxel via Reducing Multidrug Resistance and Promoting Apoptosis

Deneddylation of ribosomal proteins promotes synergy between MLN4924 and chemotherapy to elicit complete therapeutic responses

LY2228820 induces synergistic anti-cancer effects with anti-microtubule chemotherapeutic agents independent of P-glycoprotein in multidrug resistant cancer cells.

Polymeric Nanomedicine for Combined Gene/Chemotherapy Elicits Enhanced Tumor Suppression

Nanocarrier mediated entinostat and oxaliplatin combination therapy displayed enhanced efficacy against pancreatic cancer

Combination chemotherapy against colorectal cancer cells: Co-delivery of capecitabine and pioglitazone hydrochloride by polycaprolactone-polyethylene glycol carriers

pH-Sensitive Nanodrug Carriers for Codelivery of ERK Inhibitor and Gemcitabine Enhance the Inhibition of Tumor Growth in Pancreatic Cancer

Synergistic nanoparticulate drug combination overcomes multidrug resistance, increases efficacy, and reduces cardiotoxicity in a nonimmunocompromised breast tumor model

Histone deacetylase inhibition overcomes drug resistance through a miRNA-dependent mechanism

An innovative synergistic combination using eudragit-coated galactosylated PLGA-pluronic nanoparticles for addressing colorectal cancer

Codelivery of Doxorubicin/PI3K Inhibitor Nanomicelle Linked with Phenylboronic Acid for Enhanced Cytotoxicity to Pancreatic Cancer

Repurposing HDAC and mTOR inhibitors for pancreatic cancer.

A multi-functional nano-system combining PI3K-110α/β inhibitor overcomes P-glycoprotein mediated MDR and improves anti-cancer efficiency

Synergistic Disruption of Metabolic Homeostasis through Hyperbranched Poly(ethylene glycol) Conjugates as Nanotherapeutics to Constrain Cancer Growth

Celastrol Derivative/DOX Co-Assembled Nanodrug for Enhanced Antitumor Therapy

Co-drug delivery of regorafenib and cisplatin with amphiphilic copolymer nanoparticles: enhanced in vivo antitumor cancer therapy in nursing care

Targeting Death Receptors for Drug-Resistant Cancer Therapy: Codelivery of Ptrail and Monensin Using Dual-Targeting and Stimuli-Responsive Self-Assembling Nanocomposites